Latest Integral membrane proteins Stories
Eli Lilly & Co has ended a clinical trial for an Alzheimer's disease drug during the middle of the study after patients showed abnormal liver biochemical tests.
Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease.
Researchers have found that the brains of patients with early-onset Alzheimer's produce about 20 percent more of a protein fragment known as amyloid beta 42 than family members without the disease.
Scientists at the University of Liverpool and Callaghan Innovation in New Zealand have developed a new chemical approach to help harness the natural ability of complex sugars to treat Alzheimer's disease.
According to a group researchers, tests of the anti-cancer drug bexarotene failed to stop the formation of the amyloid brain plaques that are associated with Alzheimer’s disease, conflicting with the results of an identical 2012 study.
MetLife Foundation today announced the recipients of its 2013 Awards for Medical Research in Alzheimer’s Disease: Yueming Li, Ph.D., member and professor, Sloan-Kettering Institute and director
Many Alzheimer’s disease researchers are focused on stopping the buildup of amyloid plaques, dense protein deposits that are a telltale sign of the debilitating disease. However, a group of scientists from the Salk Institute for Biological Studies decision to think outside the box and pursue a different treatment strategy has paid off.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.